Studies demonstrate key findings for Novartis compounds to address unmet treatment needs of patients with cancer and rare diseases
Novartis will showcase the clinical progress of multiple marketed and pipeline compounds with 160 abstracts at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) scheduled from June 1-5 in Chicago. These studies demonstrate key findings for Novartis compounds to address unmet treatment needs of patients with cancer and rare diseases. It includes updated data in advanced breast cancer.
“Among the data we will share at this year’s ASCO are results from our key products, Afinitor and Tasigna, which demonstrate the magnitude of benefit these treatments may provide for patients with some types of advanced breast cancer and chronic myeloid leukemia,” said Hervé Hoppenot, President, Novartis Oncology. “In addition, we are seeing promising data from our early pipeline across multiple disease areas, including non-small cell lung cancer, multiple myeloma, NRAS-mutated melanoma and other solid tumours.”
EP News Bureau-Mumbai